sulfinpyrazone has been researched along with Cardiovascular Diseases in 15 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent." | 3.75 | Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. ( Margulies, EH; Sherry, S; White, AM, 1980) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| " Starting dosage was 200 mg per day; daily dosage was then increased, every 4 days, by 200 mg or kept constant for another 4 days, according to each patient's basal renal function, up to the maintenance dose: 800 mg/day." | 1.27 | Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule. ( Borghi, C; Dacco', L; Di Ruvo, R; Palummeri, E; Passeri, M, 1984) |
| " Each patient was allocated, according to his/her baseline values of serum uric acid or serum creatinine to four different sulphinpyrazone incremental dosage schedules." | 1.27 | Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment. ( Bertoli, L; Borghi, C; Busnardo, I; Zagnoni, P, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Friedewald, WT | 1 |
| Schoenberger, JA | 1 |
| Palummeri, E | 1 |
| Borghi, C | 2 |
| Di Ruvo, R | 1 |
| Dacco', L | 1 |
| Passeri, M | 1 |
| Giannini, SD | 1 |
| Sanchis, FS | 1 |
| Guerra, JL | 1 |
| Merusse, JL | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Margulies, EH | 1 |
| White, AM | 1 |
| Sherry, S | 1 |
| Weiss, HJ | 1 |
| Turpie, AG | 1 |
| Boeynaems, JM | 1 |
| Jobin, F | 1 |
| Rubegni, M | 1 |
| Provvedi, D | 1 |
| Bellini, PG | 1 |
| Bandinelli, C | 1 |
| De Mauro, G | 1 |
| Gantmacher, ML | 1 |
| Borhani, NO | 1 |
| Harker, LA | 1 |
| Bertoli, L | 1 |
| Busnardo, I | 1 |
| Zagnoni, P | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
7 reviews available for sulfinpyrazone and Cardiovascular Diseases
| Article | Year |
|---|---|
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents; Arterioscl | 1976 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
3 trials available for sulfinpyrazone and Cardiovascular Diseases
| Article | Year |
|---|---|
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
8 other studies available for sulfinpyrazone and Cardiovascular Diseases
| Article | Year |
|---|---|
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule.
Topics: Aged; Cardiovascular Diseases; Drug Administration Schedule; Drug Tolerance; Female; Humans; Kidney | 1984 |
[Cardiovascular lesions induced in rats by vitamin D. Possible protective effect of sulfinpyrazone].
Topics: Animals; Arteries; Cardiovascular Diseases; Dipyridamole; Male; Myocardium; Necrosis; Oxyphenbutazon | 1983 |
[Prevention of cardiovascular diseases by inhibitors of platelet aggregation (author's transl)].
Topics: Anti-Inflammatory Agents; Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Platelet Aggregati | 1982 |
[Anti-platelet aggregating drugs in the prevention of thromboembolic diseases].
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cardiovascular Diseases; Cerebrovascular Diso | 1975 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment.
Topics: Allopurinol; Cardiovascular Diseases; Creatinine; Drug Tolerance; Female; Humans; Kidney Function Te | 1985 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |